Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp dohme limited - sulfat vorapaxar - infart mijokardijaku - aġenti antitrombotiċi - zontivityis indikat għat-tnaqqis ta 'episodji aterotrombotiċi f'pazjenti adulti bil - storja ta' infart mijokardijaku (mi)l-ko-amministrat ma 'acetylsalicylic acid (asa) u, fejn xieraq, clopidogrel; jew - sintomatika mard arterjali periferali(pad), mogħti flimkien ma' acetylsalicylic acid (asa) jew, fejn xieraq, clopidogrel.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemofilja a - sustanzi kontra l-emorraġija - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra jistgħu jintużaw fil-gruppi kollha tal-età.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - nonacog alfa - hemofilja b - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja b (nuqqas konġenitali ta' fattur ix).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - daptomycin - gram-positive bacterial infections; bacteremia; soft tissue infections; endocarditis, bacterial - antibatteriċi għal użu sistemiku, - cubicin huwa indikat għat-trattament ta 'l-infezzjonijiet li ġejjin. adulti u pedjatriċi (1-17-il sena) ta ' pazjenti b'infezzjonijiet ikkumplikati tal-ġilda u tat-tessuti rotob (cssti). pazjenti adulti bi dritt naħat endokardite infettiva (rie) minn staphylococcus aureus. huwa rakkomandat li d-deċiżjoni li jintuża daptomycin għandha tieħu in kunsiderazzjoni l-suxxettibilità antibatterika ta 'l-organiżmu u għandha tkun ibbażata fuq parir ta' espert. adulti u pedjatriċi (1-17-il sena) il-pazjenti bil-batterimja minn staphylococcus aureus (sab). fl-adulti, l-użu fl-batterimja għandha tkun assoċjata ma 'rie jew ma' cssti, filwaqt li fil-pazjenti pedjatriċi, l-użu fl-batterimja għandu jkun assoċjat ma ' cssti. daptomycin huwa attiv kontra batteri gram posittivi biss. imħallat ta 'l-infezzjonijiet fejn gram negattivi u/jew ċerti tipi ta' batterji anerobiċi huma suspettati, cubicin għandu jingħata flimkien ma ' sustanza anti batterjali xierqa(i). għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - aġenti antineoplastiċi oħra - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - antithrombin alfa - defiċjenza ta 'antithrombin iii - aġenti antitrombotiċi - atryn huwa indikat għall-profilassi ta 'tromboemboliżmu fil-vini fil-kirurġija ta' pazjenti b'defiċjenza konġenitali ta 'antithrombin. atryn normalment jingħata flimkien ma 'eparina jew eparina b'piż molekulari baxx.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimikotiċi għal użu sistemiku - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - majloma multipla - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.